BMRNNASDAQ| BioMarin Pharmaceuticals golden cross and death cross

On the daily chart the 50 SMA has sat above the 200 since Jul, and price is trading above both. No cross is projected on the daily or the weekly inside the 30 bars we track.

On the daily, BMRN has crossed 20 times, roughly every 6 months, the last one on 7/22/2026. On the weekly it has crossed 6 times, most recently a death cross in Aug 2024, with price trading below the 50/200 cross point that day. It closed the following week 6% higher.

BMRN  

Loading the chart...

BMRN cross history: every 50/200 cross since 2017

42 golden and death crosses since 2017, with 6 on the weekly timeframe. We projected all 20 daily crosses from a median of 24 bars out. The most recent was a golden cross on the daily, on 7/22/2026.

Crossed
7/22/2026Goldendaily
7/6/2026Golden4-hour
5/7/2026Deathdaily
4/8/2026Death4-hour
2/9/2026Goldendaily
12/29/2025Golden4-hour
9/4/2025Death4-hour
8/26/2025Golden4-hour
4/17/2025Death4-hour
3/5/2025Golden4-hour
9/25/2024Death4-hour
8/23/2024Deathweekly
7/24/2024Golden4-hour
3/19/2024Deathdaily
2/23/2024Death4-hour
1/10/2024Goldendaily
12/11/2023Golden4-hour
9/29/2023Death4-hour
9/27/2023Golden4-hour
9/26/2023Death4-hour
9/12/2023Golden4-hour
5/2/2023Deathdaily
3/16/2023Death4-hour
11/18/2022Goldenweekly
11/4/2022Deathweekly
10/21/2022Goldenweekly
8/8/2022Goldendaily
4/21/2022Deathdaily
11/24/2021Goldendaily
8/18/2021Deathdaily
7/15/2021Goldendaily
5/28/2021Deathweekly
9/29/2020Deathdaily
8/7/2020Goldenweekly
1/9/2020Goldendaily
1/2/2019Deathdaily
6/18/2018Goldendaily
3/1/2018Deathdaily
2/15/2018Goldendaily
11/14/2017Deathdaily
10/24/2017Goldendaily
8/22/2017Deathdaily

Click any cross on the chart above for its lead time. Crosses from 2 September 2026 onward were watched live; earlier ones are replayed from the archive with no look-ahead, which is the same method behind the published track record.

Cruxta · 50/200 moving-average crosses on US equities. Recorded crosses are observations. Projected crosses are projections, not advice.